Compare · BDX vs CERS
BDX vs CERS
Side-by-side comparison of Becton Dickinson and Company (BDX) and Cerus Corporation (CERS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and CERS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $58.96B, about 157.4x CERS ($374.7M).
- BDX has been more active in the news (11 items in the past 4 weeks vs 7 for CERS).
- BDX has more recent analyst coverage (25 ratings vs 4 for CERS).
- Company
- Becton Dickinson and Company
- Cerus Corporation
- Price
- -
- -
- Market cap
- $58.96B
- $374.7M
- 1M return
- +12.87%
- -
- 1Y return
- +44.14%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1997
- News (4w)
- 11
- 7
- Recent ratings
- 25
- 4
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Cerus Corporation
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation has collaboration with LifeSouth Community Blood Centers to manufacture INTERCEPT Fibrinogen Complex. The company was incorporated in 1991 and is headquartered in Concord, California.
Latest BDX
- Director Huffines Robert Luther was granted 158 units of Rights to Common Stock Under BD Deferred Compensation Plan (SEC Form 4)
- Director Byington Carrie L was granted 79 units of Rights to Common Stock Under 1996 Directors Deferral Plan (SEC Form 4)
- BD to Host Investor Day on December 10, 2026
- Chairman, CEO and President Polen Thomas E Jr exercised 20,239 shares at a strike of $178.94, returned $3,621,660 worth of shares to the company (17,246 units at $210.00) and sold $628,530 worth of shares (2,993 units at $210.00) as part of a pre-agreed trading plan (SEC Form 4)
- Becton Dickinson upgraded by Wells Fargo with a new price target
- Becton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- BD Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results
- BD Board Increases Dividend for 55th Consecutive Year, Authorizes 10 Million Additional Share Repurchases
- BD Names Bridget Bagnato Worldwide President of Peripheral Intervention
- BD Advances Portal Hypertension Care in the U.S. with Support for More Personalized Treatment Options
Latest CERS
- Amendment: SEC Form SCHEDULE 13G/A filed by Cerus Corporation
- Cerus Corporation to Participate in the 17th Annual Craig-Hallum Alpha Select Conference
- SEC Form S-3 filed by Cerus Corporation
- SEC Form 10-Q filed by Cerus Corporation
- Cerus Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Cerus Corporation Announces Third Quarter 2026 Financial Results
- Cerus Corporation Announces Positive Topline Results from Phase 3 RedeS Trial of the INTERCEPT Blood System for Red Blood Cells
- Cerus Corporation to Release Third Quarter 2026 Financial Results on November 2, 2026
- Cerus Corporation Announces Workshop and Abstracts at the 2026 AABB Annual Meeting
- Chief Legal Officer Jensen Chrystal sold $89,529 worth of shares (30,000 units at $2.98) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 936,657 units (SEC Form 4)